Manufacturer of Controlled Substances Notice of Application, 21298 [E7-8131]
Download as PDF
<![CDATA[
21298
Federal Register / Vol. 72, No. 82 / Monday, April 30, 2007 / Notices
mockery of judicial power.’’ SBC
Commc’ns, at *14.
In 2004, Congress amended the APPA
to ensure that courts take into account
the above-quoted list of relevant factors
when making a public interest
determination. Compare 15 U.S.C. 16(e)
(2004) with 15 U.S.C. 16(e)(1) (2006)
(substituting ‘‘shall’’ for ‘‘may’’ in
directing relevant factors for court to
consider and amending list of factors to
focus on competitive considerations and
to address potentially ambiguous
judgment terms). These amendments,
however, did not change the
fundamental role of courts in reviewing
proposed settlements. To the contrary,
Congress made clear its intent to
preserve the practical benefits of
utilizing consent decrees in antitrust
enforcement, adding the unambiguous
instruction ‘‘[n]othing in this section
shall be construed to require the court
to conduct an evidentiary hearing or to
require the court to permit anyone to
intervene.’’ 15 U.S.C. 16 (e)(2). This
language codified the intent of the
original 1974 statute, expressed by
Senator Tunney in the legislative
history: ‘‘[t]he court is nowhere
compelled to go to trial or to engage in
extended proceedings which might have
the effect of vitiating the benefits of
prompt and less costly settlement
through the consent decree process.’’
119 Cong. Rec. 24,598 (1973) (statement
of Senator Tunney). Rather:
rwilkins on PROD1PC63 with NOTICES
[a]bsent a showing of corrupt failure of the
government to discharge its duty, the Court,
in making its public interest finding, should
. . . carefully consider the explanations of
the government in the competitive impact
statement and its responses to comments in
order to determine whether those
explanations are reasonable under the
circumstances.
United States v. Mid-America Dairymen, Inc.,
1977–1 Trade Cas. (CCH) ¶ 61,508, at 71,980
(W.D. Mo. 1977).
This-Court recently examined the role of
the district court in reviewing proposed final
judgments in light of the 2004 amendments,
confirming that the amendments ‘‘effected
minimal changes[] and that this Court’s scope
of review remains sharply proscribed by
precedent and the nature of Tunney Act
proceedings.’’ See United States v. SBC
Commc’ns, Inc., Nos. 05–2102 and 05–2103,
2007 WL 1020746, at *9 (D.D.C. Mar. 29,
2007). This Court concluded that the
amendments did not alter the articulation of
the public interest standard in Microsoft. Id.
at *15.
VIII. Determinative Documents
There are no determinative materials or
documents within the meaning of the APPA
that were considered by the United States in
formulating the proposed Final Judgment.
Dated: April 18, 2007.
Respectfully submitted,
VerDate Aug<31>2005
18:27 Apr 27, 2007
Jkt 211001
/s/ lllllllllllllllll
C. Scott Hataway Bar No. 473942,
U.S. Department of Justice, Antitrust
Division, Lit II Section, 1401 H Street
NW., Washington, DC 20530 202–514–
8380.
[FR Doc. 07–2087 Filed 4–27–07; 8:45am]
BILLING CODE 4410–11–M
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Importer of Controlled Substances
Notice of Application
This is notice that on October 18,
2006, Noramco Inc., 500 Swedes
Landing Road, Wilmington, Delaware
19801, made application by renewal to
the Drug Enforcement Administration
(DEA) for registration as an importer of
the basic classes of controlled
substances listed in schedule II:
Drug
Schedule
Raw Opium (9600) .......................
Concentrate of Poppy Straw
(9670).
II
II
The company plans to import the
listed controlled substances to
manufacture other controlled
substances.
As noted in a previous notice
published in the Federal Register on
September 23, 1975, (40 FR 43745), all
applicants for registration to import a
basic class of any controlled substances
in schedule I or II are, and will continue
to be, required to demonstrate to the
Deputy Assistant Administrator, Office
of Diversion Control, Drug Enforcement
Administration, that the requirements
for such registration pursuant to 21
U.S.C. 958(a), 21 U.S.C. 823(a), and 21
CFR 1301.34(b), (c), (d), (e) and (f) are
satisfied.
Dated: April 17, 2007.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control Drug Enforcement
Administration.
[FR Doc. E7–8132 Filed 4–27–07; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled
Substances Notice of Application
Pursuant to § 1301.33(a) of Title 21 of
the Code of Federal Regulations (CFR),
this is notice that on March 1, 2007,
Organichem Corporation, 33 Riverside
PO 00000
Frm 00097
Fmt 4703
Sfmt 4703
Avenue, Rensselaer, New York 12144,
made application by letter to the Drug
Enforcement Administration (DEA) to
be registered as a bulk manufacturer of
Oxymorphone (9652), a basic class of
controlled substance listed in schedule
II.
The company plans on manufacturing
the listed controlled substance in bulk
for sale to its customers.
Any other such applicant and any
person who is presently registered with
DEA to manufacture such a substance
may file comments or objections to the
issuance of the proposed registration
pursuant to 21 CFR 1301.33(a).
Any such written comments or
objections being sent via regular mail
should be addressed, in quintuplicate,
to the Drug Enforcement
Administration, Office of Diversion
Control, Attention: DEA Federal
Register Representative (ODL),
Washington, DC 20537, or any being
sent via express mail should be sent to
Drug Enforcement Administration,
Office of Diversion Control, Federal
Register Representative (ODL), 2401
Jefferson-Davis Highway, Alexandria,
Virginia 22301; and must be filed no
later than June 29, 2007.
Dated: April 17, 2007.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control Drug Enforcement
Administration.
[FR Doc. E7–8131 Filed 4–27–07; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Importer of Controlled Substances
Notice of Application
This is notice that on January 26,
2007, Stepan Company, Natural
Products Department, 100 W. Hunter
Avenue, Maywood, New Jersey 07607,
made application by renewal to the
Drug Enforcement Administration
(DEA) for registration as an importer of
Coca Leaves (9040), a basic class of
controlled substance listed in schedule
II.
The company plans to import the
listed controlled substance for the
manufacture of a bulk controlled
substance for distribution to its
customer.
As noted in a previous notice
published in the Federal Register on
September 23, 1975, (40 FR 43745), all
applicants for registration to import a
basic class of any controlled substances
in schedule I or II are, and will continue
to be, required to demonstrate to the
E:\FR\FM\30APN1.SGM
30APN1
]]>Agencies
[Federal Register Volume 72, Number 82 (Monday, April 30, 2007)]
[Notices]
[Page 21298]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E7-8131]
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled Substances Notice of Application
Pursuant to Sec. 1301.33(a) of Title 21 of the Code of Federal
Regulations (CFR), this is notice that on March 1, 2007, Organichem
Corporation, 33 Riverside Avenue, Rensselaer, New York 12144, made
application by letter to the Drug Enforcement Administration (DEA) to
be registered as a bulk manufacturer of Oxymorphone (9652), a basic
class of controlled substance listed in schedule II.
The company plans on manufacturing the listed controlled substance
in bulk for sale to its customers.
Any other such applicant and any person who is presently registered
with DEA to manufacture such a substance may file comments or
objections to the issuance of the proposed registration pursuant to 21
CFR 1301.33(a).
Any such written comments or objections being sent via regular mail
should be addressed, in quintuplicate, to the Drug Enforcement
Administration, Office of Diversion Control, Attention: DEA Federal
Register Representative (ODL), Washington, DC 20537, or any being sent
via express mail should be sent to Drug Enforcement Administration,
Office of Diversion Control, Federal Register Representative (ODL),
2401 Jefferson-Davis Highway, Alexandria, Virginia 22301; and must be
filed no later than June 29, 2007.
Dated: April 17, 2007.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of Diversion Control Drug
Enforcement Administration.
[FR Doc. E7-8131 Filed 4-27-07; 8:45 am]
BILLING CODE 4410-09-P
